12:00 AM
Sep 15, 2014
 |  BC Week In Review  |  Company News  |  Deals

Ligand, Avion deal

Ligand granted Avion undisclosed development and commercialization rights to four undisclosed programs using Ligand's Captisol formulation technology. Ligand will receive an undisclosed upfront payment and...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >